What is all the fuss about the human papillomavirus (HPV) vaccine?

Cervical cancer is quite common all over the world. The tragedy of cervical cancer is that it affects young females. Current estimates indicate that in America, approximately 11,000 women develop cervical cancer and there are about 3,000 deaths each year. Over the years, a strong link between the human papilloma virus (HPV) and cervical cancer has been established. Furthermore, HPV has also been linked to cancers of the mouth, vulva, anus, and penis. With more people engaging in sexual activities at an earlier age, a vaccine would be a great way to prevent these cancers associated with HPV.

At present two vaccines have been developed to prevent infection from HPV. Both vaccines are administered by an injection in three divided doses. The current injection guidelines recommend that the first injection be followed by the 2nd and 3rd dose, two and six months, apart.

So far, only one vaccine is currently available in North America. Gardasil is currently available and recommended for all girls and young women between the ages of 9 and 26. In different countries, the age of vaccination is slightly variable. For example in Australia, cervarix is recommended for all females between the ages of 10-45 and for boys in-between the ages of 9-15. Cervarix is currently in the clinical trials stage in North America but data indicate that it is just as effective and safe as Gardasil.

The most important factor with both vaccines is that one gets vaccinated prior to becoming sexually active. Current data indicate that if the vaccine is injected in sexually active individuals, it does not get rid of HPV infection and thus protection against cervical cancer is not a guarantee.